Nicholas F Larusso

List of Publications by Year
in descending order

243 papers	23,670 citations	5574 82 h-index	8866 145 g-index
251 all docs	251 docs citations	251 times ranked	17909 citing authors

#	Article	IF	Citations
1	The Achillesâ€™ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell, 2015, 14, 644-658.	6.7	1,534
2	Biliary Tract Cancers. New England Journal of Medicine, 1999, 341, 1368-1378.	27.0	933
3	Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysis. Hepatology, 1989, 10, 430-436.	7.3	622
4	Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology, 1980, 79, 200-206.	1.3	541
5	Cryptosporidiosis. New England Journal of Medicine, 2002, 346, 1723-1731.	27.0	451
6	A Cellular Micro-RNA, let-7i, Regulates Toll-like Receptor 4 Expression and Contributes to Cholangiocyte Immune Responses against Cryptosporidium parvum Infection. Journal of Biological Chemistry, 2007, 282, 28929-28938.	3.4	409
7	The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. American Journal of Gastroenterology, 2000, 95, 204-207.	0.4	376
8	An aged immune system drives senescence and ageing of solid organs. Nature, 2021, 594, 100-105.	27.8	368
9	Primary Sclerosing Cholangitis. New England Journal of Medicine, 2016, 375, 1161-1170.	27.0	358
10	Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology, 1999, 29, 1050-1056.	7.3	344
11	Cholangiocarcinoma Complicating Primary Sclerosing Cholangitis. Annals of Surgery, 1991, 213, 21-25.	4.2	337
12	Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology, 1999, 30, 1121-1127.	7.3	329
13	The cholangiopathies: Disorders of biliary epithelia. Gastroenterology, 2004, 127, 1565-1577.	1.3	326
14	Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology, 1981, 1, 632-640.	7.3	325
15	Characterization of PKD Protein-Positive Exosome-Like Vesicles. Journal of the American Society of Nephrology: JASN, 2009, 20, 278-288.	6.1	300
16	Randomized Clinical Trial of Long-Acting Somatostatin for Autosomal Dominant Polycystic Kidney and Liver Disease. Journal of the American Society of Nephrology: JASN, 2010, 21, 1052-1061.	6.1	288
17	Cholangiocyte pathobiology. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 269-281.	17.8	285
18	The isolated perfused rat liver: Conceptual and practical considerations. Hepatology, 1986, 6, 511-517.	7.3	264

#	Article	IF	Citations
19	Octreotide Inhibits Hepatic Cystogenesis in a Rodent Model of Polycystic Liver Disease by Reducing Cholangiocyte Adenosine 3â€²,5â€²-Cyclic Monophosphate. Gastroenterology, 2007, 132, 1104-1116.	1.3	261
20	Cholangiocyte Cilia Detect Changes in Luminal Fluid Flow and Transmit Them Into Intracellular Ca2+ and cAMP Signaling. Gastroenterology, 2006, 131, 911-920.	1.3	259
21	MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology, 2009, 49, 1595-1601.	7.3	247
22	Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. American Journal of Physiology - Renal Physiology, 2001, 281, G626-G634.	3.4	236
23	Primary sclerosing cholangitis: Summary of a workshop. Hepatology, 2006, 44, 746-764.	7.3	235
24	Biliary exosomes influence cholangiocyte regulatory mechanisms and proliferation through interaction with primary cilia. American Journal of Physiology - Renal Physiology, 2010, 299, G990-G999.	3.4	234
25	Nitric oxideâ€"mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes. Gastroenterology, 2001, 120, 190-199.	1.3	212
26	Diagnostic Role of Serum CA 19-9 for Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis. Mayo Clinic Proceedings, 1993, 68, 874-879.	3.0	207
27	Comparison of the Clinicopathologic Features of Primary Sclerosing Chol-angitis and Primary Biliary Cirrhosis. Gastroenterology, 1985, 88, 108-114.	1.3	205
28	Multiple TLRs Are Expressed in Human Cholangiocytes and Mediate Host Epithelial Defense Responses to <i>Cryptosporidium parvum</i> via Activation of NF-Î°B. Journal of Immunology, 2005, 175, 7447-7456.	0.8	199
29	Up-regulation of microRNA 506 leads to decreased Clâ^'/HCO3â^' anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. Hepatology, 2012, 56, 687-697.	7.3	199
30	Isolation and morphologic characterization of bile duct epithelial cells from normal rat liver. Gastroenterology, 1989, 97, 1236-1247.	1.3	196
31	Defects in cholangiocyte fibrocystin expression and ciliary structure in the PCK rat1 1The authors thank Dr. Torra for supplying ARPKD tissue.. Gastroenterology, 2003, 125, 1303-1310.	1.3	194
32	Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis. Hepatology, 2014, 59, 2263-2275.	7.3	194
33	MicroRNA-513 Regulates B7-H1 Translation and Is Involved in IFN-Î³-Induced B7-H1 Expression in Cholangiocytes. Journal of Immunology, 2009, 182, 1325-1333.	0.8	190
34	Extracellular vesicles in liver pathobiology: Small particles with big impact. Hepatology, 2016, 64, 2219-2233.	7.3	190
35	Cholangiocyte cilia express TRPV4 and detect changes in luminal tonicity inducing bicarbonate secretion. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19138-19143.	7.1	186
36	Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis. Hepatology, 2016, 63, 185-196.	7.3	183

#	Article	IF	Citations
37	Physiology of Cholangiocytes. , 2013, 3, 541-565.		179
38	Secretin Promotes Osmotic Water Transport in Rat Cholangiocytes by Increasing Aquaporin-1 Water Channels in Plasma Membrane. Journal of Biological Chemistry, 1997, 272, 12984-12988.	3.4	178
39	The Water Channel Aquaporin-8 Is Mainly Intracellular in Rat Hepatocytes, and Its Plasma Membrane Insertion Is Stimulated by Cyclic AMP. Journal of Biological Chemistry, 2001, 276, 12147-12152.	3.4	177
40	HDAC6 Inhibition Restores Ciliary Expression and Decreases Tumor Growth. Cancer Research, 2013, 73, 2259-2270.	0.9	175
41	Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology, 1988, 95, 1036-1042.	1.3	168
42	The Cholangiopathies. Mayo Clinic Proceedings, 2015, 90, 791-800.	3.0	167
43	Recent advances in the isolation of liver cells. Hepatology, 1994, 20, 494-514.	7.3	160
44	Release of Luminal Exosomes Contributes to TLR4-Mediated Epithelial Antimicrobial Defense. PLoS Pathogens, 2013, 9, e1003261.	4.7	159
45	MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. Journal of Clinical Investigation, 2008, 118, 3714-3724.	8.2	158
46	Peristomal varices after proctocolectomy in patients with primary sclerosing cholangitis. Gastroenterology, 1986, 90, 316-322.	1.3	147
47	Cholangiocyte primary cilia are chemosensory organelles that detect biliary nucleotides via P2Y₁₂ purinergic receptors. American Journal of Physiology - Renal Physiology, 2008, 295, G725-G734.	3.4	147
48	Cholangiocyte primary cilia in liver health and disease. Developmental Dynamics, 2008, 237, 2007-2012.	1.8	142
49	Cryptosporidium parvum activates nuclear factor ÎºB in biliary epithelia preventing epithelial cell apoptosis. Gastroenterology, 2001, 120, 1774-1783.	1.3	135
50	The pathobiology of biliary epithelia. Hepatology, 2002, 35, 1256-1268.	7.3	135
51	Expression and Localization of Aquaporin Water Channels in Rat Hepatocytes. Journal of Biological Chemistry, 2002, 277, 22710-22717.	3.4	131
52	Elevated Circulating Immune Complexes in Primary Sclerosing Cholangitis. Hepatology, 1983, 3, 150-154.	7.3	131
53	Water transport by epithelia of the digestive tract. Gastroenterology, 2002, 122, 545-562.	1.3	130
54	The dynamic biliary epithelia: Molecules, pathways, and disease. Journal of Hepatology, 2013, 58, 575-582.	3.7	130

#	Article	IF	Citations
55	Effect of Deoxycholic Acid Ingestion on Bile Acid Metabolism and Biliary Lipid Secretion in Normal Subjects. Gastroenterology, 1977, 72, 132-140.	1.3	129
56	Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology, 2003, 124, 737-753.	1.3	129
57	Cyclic AMP Regulates Bicarbonate Secretion in Cholangiocytes Through Release of ATP Into Bile. Gastroenterology, 2007, 133, 1592-1602.	1.3	126
58	The relative role of the child-pugh classification and the mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology, 1999, 29, 1643-1648.	7.3	124
59	Ciliary subcellular localization of TGR5 determines the cholangiocyte functional response to bile acid signaling. American Journal of Physiology - Renal Physiology, 2013, 304, G1013-G1024.	3.4	122
60	Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrology Dialysis Transplantation, 2012, 27, 3532-3539.	0.7	120
61	Heterogeneity of the proliferative capacity of rat cholangiocytes after bile duct ligation. American Journal of Physiology - Renal Physiology, 1998, 274, G767-G775.	3.4	119
62	Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice. Journal of Hepatology, 2018, 69, 676-686.	3.7	119
63	Effect of Proctocolectomy for Chronic Ulcerative Colitis on the Natural History of Primary Sclerosing Cholangitis. Gastroenterology, 1989, 96, 790-794.	1.3	118
64	The metabolic bone disease of primary sclerosing cholangitis. Hepatology, 1991, 14, 257-261.	7.3	115
65	Manifestations of nonsuppurative cholangitis in chronic hepatobiliary diseases: morphologic spectrum, clinical correlations and terminology. Liver, 1984, 4, 105-116.	0.1	113
66	A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. Journal of Hepatology, 2020, 73, 94-101.	3.7	111
67	Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology, 2006, 44, 1465-1477.	7.3	110
68	The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD). Hepatology, 2009, 49, 160-174.	7.3	110
69	Agonist-induced Coordinated Trafficking of Functionally Related Transport Proteins for Water and Ions in Cholangiocytes. Journal of Biological Chemistry, 2003, 278, 20413-20419.	3.4	108
70	Mechanisms of attachment and internalization of Cryptosporidium parvum to biliary and intestinal epithelial cells. Gastroenterology, 2000, 118, 368-379.	1.3	106
71	Biliary Dysgenesis in the PCK Rat, an Orthologous Model of Autosomal Recessive Polycystic Kidney Disease. American Journal of Pathology, 2004, 165, 1719-1730.	3.8	105
72	Coordinate Secretion of Acid Hydrolases in Rat Bile. Journal of Clinical Investigation, 1979, 64, 948-954.	8.2	104

#	Article	IF	Citations
73	Spontaneous DNA damage to the nuclear genome promotes senescence, redox imbalance and aging. Redox Biology, 2018, 17, 259-273.	9.0	103
74	Cryptosporidium parvum is cytopathic for cultured human biliary epithelia via an apoptotic mechanism. Hepatology, 1998, 28, 906-913.	7.3	102
75	Targeting senescent cholangiocytes and activated fibroblasts with Bâ€cell lymphomaâ€extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2â^'/â^') mice. Hepatology, 2018, 67, 247-259.	7.3	99
76	NFÎºB p50-CCAAT/Enhancer-binding Protein Î² (C/EBPÎ²)-mediated Transcriptional Repression of MicroRNA let-7i following Microbial Infection. Journal of Biological Chemistry, 2010, 285, 216-225.	3.4	97
77	Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology, 2013, 58, 409-421.	7.3	96
78	Isolation and characterization of cholangiocyte primary cilia. American Journal of Physiology - Renal Physiology, 2006, 291, G500-G509.	3.4	95
79	MicroRNAs: Key Modulators of Posttranscriptional Gene Expression. Gastroenterology, 2009, 136, 17-25.	1.3	95
80	Anatomy of the human biliary system studied by quantitative computer-aided three-dimensional imaging techniques. Hepatology, 1998, 27, 893-899.	7.3	93
81	Intrahepatic cholangiectases and large-duct obliteration in primary sclerosing cholangitis. Hepatology, 1986, 6, 560-568.	7.3	90
82	Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning. Hepatology, 2020, 71, 214-224.	7.3	90
83	Validity and Sensitivity of an Intravenous Bile Acid Tolerance Test in Patients with Liver Disease. New England Journal of Medicine, 1975, 292, 1209-1214.	27.0	88
84	Polarized expression and function of P2Y ATP receptors in rat bile duct epithelia. American Journal of Physiology - Renal Physiology, 2001, 281, G1059-G1067.	3.4	85
85	Proteolytic Cleavage and Nuclear Translocation of Fibrocystin Is Regulated by Intracellular Ca2+ and Activation of Protein Kinase C. Journal of Biological Chemistry, 2006, 281, 34357-34364.	3.4	85
86	Activation of Trpv4 Reduces the Hyperproliferative Phenotype of Cystic Cholangiocytes From an Animal Model of ARPKD. Gastroenterology, 2010, 139, 304-314.e2.	1.3	85
87	Characterization of cultured cholangiocytes isolated from livers of patients with primary sclerosing cholangitis. Laboratory Investigation, 2014, 94, 1126-1133.	3.7	85
88	Localized glucose and water influx facilitates Cryptosporidium parvum cellular invasion by means of modulation of host-cell membrane protrusion. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 6338-6343.	7.1	84
89	Cholangiociliopathies: genetics, molecular mechanisms and potential therapies. Current Opinion in Gastroenterology, 2009, 25, 265-271.	2.3	83
90	Performance of magnetic resonance elastography in primary sclerosing cholangitis. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1184-1190.	2.8	83

#	Article	IF	Citations
91	Abnormalities in tests of copper metabolism in primary sclerosing cholangitis. Gastroenterology, 1985, 89, 272-278.	1.3	80
92	Polycystic liver diseases: advanced insights into the molecular mechanisms. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 750-761.	17.8	80
93	Regulation of Ca2+ signaling in rat bile duct epithelia by inositol 1,4,5-trisphosphate receptor isoforms. Hepatology, 2002, 36, 284-296.	7.3	79
94	Apical Organelle Discharge by Cryptosporidium parvum Is Temperature, Cytoskeleton, and Intracellular Calcium Dependent and Required for Host Cell Invasion. Infection and Immunity, 2004, 72, 6806-6816.	2.2	77
95	Glucagon induces the plasma membrane insertion of functional aquaporin-8 water channels in isolated rat hepatocytes. Hepatology, 2003, 37, 1435-1441.	7.3	76
96	Secretin induces the apical insertion of aquaporin-1 water channels in rat cholangiocytes. American Journal of Physiology - Renal Physiology, 1999, 276, G280-G286.	3.4	75
97	Cryptosporidium parvum invasion of biliary epithelia requires host cell tyrosine phosphorylation of cortactin via c-Src. Gastroenterology, 2003, 125, 216-228.	1.3	75
98	Isolation and characterization of lipid microdomains from apical and basolateral plasma membranes of rat hepatocytes. Hepatology, 2006, 43, 287-296.	7.3	75
99	The immunobiology of cholangiocytes. Immunology and Cell Biology, 2008, 86, 497-505.	2.3	74
100	Hepatic Cystogenesis Is Associated with Abnormal Expression and Location of Ion Transporters and Water Channels in an Animal Model of Autosomal Recessive Polycystic Kidney Disease. American Journal of Pathology, 2008, 173, 1637-1646.	3.8	72
101	Opisthorchis viverrini excretory/secretory products induce toll-like receptor 4 upregulation and production of interleukin 6 and 8 in cholangiocyte. Parasitology International, 2010, 59, 616-621.	1.3	72
102	MicroRNAâ€506 promotes primary biliary cholangitisâ€“like features in cholangiocytes and immune activation. Hepatology, 2018, 67, 1420-1440.	7.3	72
103	Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study. Digestive Diseases and Sciences, 1999, 44, 602-607.	2.3	70
104	Abnormalities of Chemical Tests for Copper Metabolism in Chronic Active Liver Disease: Differentiation from Wilson's Disease. Gastroenterology, 1976, 70, 653-655.	1.3	67
105	Isolation and characterization of rat cholangiocyte vesicles enriched in apical or basolateral plasma membrane domains. Biochemistry, 1995, 34, 15436-15443.	2.5	67
106	Stimulation of ATP secretion in the liver by therapeutic bile acids. Biochemical Journal, 2001, 358, 1-5.	3.7	67
107	Rat hepatocyte aquaporin-8 water channels are down-regulated in extrahepatic cholestasis. Hepatology, 2003, 37, 1026-1033.	7.3	66
108	Phosphatidylinositol 3-Kinase and Frabin Mediate Cryptosporidium parvum Cellular Invasion via Activation of Cdc42. Journal of Biological Chemistry, 2004, 279, 31671-31678.	3.4	65

#	Article	IF	Citations
109	Water Transporting Properties of Hepatocyte Basolateral and Canalicular Plasma Membrane Domains. Journal of Biological Chemistry, 2003, 278, 43157-43162.	3.4	63
110	Somatostatin stimulates ductal bile absorption and inhibits ductal bile secretion in mice via SSTR2 on cholangiocytes. American Journal of Physiology - Cell Physiology, 2003, 284, C1205-C1214.	4.6	62
111	Aquaporins in the hepatobiliary system. Hepatology, 2006, 43, S75-S81.	7.3	61
112	Enhanced autoreactivity of T-lymphocytes in primary sclerosing cholangitis. Hepatology, 1987, 7, 884-888.	7.3	60
113	Glutathione depletion is associated with decreased Bcl-2 expression and increased apoptosis in cholangiocytes. American Journal of Physiology - Renal Physiology, 1998, 275, G749-G757.	3.4	60
114	Quantitative Assessment of the Rat Intrahepatic Biliary System by Three-Dimensional Reconstruction. American Journal of Pathology, 2001, 158, 2079-2088.	3.8	59
115	Cholangiocyte N-Ras Protein Mediates Lipopolysaccharide-induced Interleukin 6 Secretion and Proliferation. Journal of Biological Chemistry, 2011, 286, 30352-30360.	3.4	59
116	Interactions between chronic liver disease and inflammatory bowel disease. Inflammatory Bowel Diseases, 1997, 3, 288-302.	1.9	58
117	Specific Inhibition of AQP1 Water Channels in Isolated Rat Intrahepatic Bile Duct Units by Small Interfering RNAs. Journal of Biological Chemistry, 2003, 278, 6268-6274.	3.4	56
118	Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. Journal of Hepatology, 2015, 63, 952-961.	3.7	56
119	Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibition. Gastroenterology, 1995, 108, 1908-1916.	1.3	55
120	Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases. Gut, 2014, 63, 1658-1667.	12.1	55
121	Milder disease stage in patients with primary biliary cholangitis over a 44â€year period: A changing natural history. Hepatology, 2018, 67, 1920-1930.	7.3	55
122	Interactions Between Chronic Liver Disease and Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 1997, 3, 288-302.	1.9	54
123	Expression of aquaporin-4 water channels in rat cholangiocytes. Hepatology, 2000, 31, 1313-1317.	7.3	54
124	MicroRNA (miR)â€433 and miRâ€22 dysregulations induce histoneâ€deacetylaseâ€6 overexpression and ciliary loss in cholangiocarcinoma. Hepatology, 2018, 68, 561-573.	7.3	54
125	Hepatic Artery and Portal Vein Remodeling in Rat Liver. American Journal of Pathology, 2003, 162, 1175-1182.	3.8	52
126	Cdc42 and the Actin-Related Protein/Neural Wiskott-Aldrich Syndrome Protein Network Mediate Cellular Invasion by Cryptosporidium parvum. Infection and Immunity, 2004, 72, 3011-3021.	2.2	52

#	Article	IF	Citations
127	Intrahepatic bile ducts transport water in response to absorbed glucose. American Journal of Physiology - Cell Physiology, 2002, 283, C785-C791.	4.6	51
128	Purinergic regulation of acid/base transport in human and rat biliary epithelial cell lines. Hepatology, 1998, 28, 914-920.	7.3	48
129	Cholangiocyte biology. Current Opinion in Gastroenterology, 2007, 23, 299-305.	2.3	48
130	Primary Sclerosing Cholangitis. New England Journal of Medicine, 2016, 375, 2500-2502.	27.0	48
131	Aquaporin water channels in liver: Their significance in bile formation. Hepatology, 1997, 26, 1081-1084.	7.3	46
132	TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/GÎ±s signaling. Hepatology, 2017, 66, 1197-1218.	7.3	46
133	Hemobilia: Etiology, diagnosis, and treatment. Liver Research, 2018, 2, 200-208.	1.4	46
134	Rat Hepatocytes Transport Water Mainly via a Non-channel-mediated Pathway. Journal of Biological Chemistry, 1996, 271, 6702-6707.	3.4	45
135	Perfused rat intrahepatic bile ducts secrete and absorb water, solute, and ions. Gastroenterology, 2000, 119, 1672-1680.	1.3	45
136	Aquaporin-8 Is Involved in Water Transport in Isolated Superficial Colonocytes from Rat Proximal Colon. Journal of Nutrition, 2005, 135, 2329-2336.	2.9	45
137	The Role of Cilia in the Regulation of Bile Flow. Digestive Diseases, 2011, 29, 6-12.	1.9	43
138	HDAC6 Is Overexpressed in Cystic Cholangiocytes and Its Inhibition Reduces Cystogenesis. American Journal of Pathology, 2014, 184, 600-608.	3.8	43
139	Ileo-colonic delivery of conjugated bile acids improves glucose homeostasis via colonic GLP-1-producing enteroendocrine cells in human obesity and diabetes. EBioMedicine, 2020, 55, 102759.	6.1	43
140	Cryptosporidium parvum infects human cholangiocytes via sphingolipid-enriched membrane microdomains. Cellular Microbiology, 2006, 8, 1932-1945.	2.1	42
141	Regulation of biliary secretion through apical purinergic receptors in cultured rat cholangiocytes. American Journal of Physiology - Renal Physiology, 1997, 273, G1108-G1117.	3.4	41
142	The Spectrum of Reactive Cholangiocytes in Primary Sclerosing Cholangitis. Hepatology, 2020, 71, 741-748.	7.3	41
143	Inhibition of Cdc25A Suppresses Hepato-renal Cystogenesis in Rodent Models of Polycystic Kidney and Liver Disease. Gastroenterology, 2012, 142, 622-633.e4.	1.3	40
144	Bile Acid Profiles in Primary Sclerosing Cholangitis and Their Ability to Predict Hepatic Decompensation. Hepatology, 2021, 74, 281-295.	7.3	40

#	Article	IF	Citations
145	Development and characterization of cholangioids from normal and diseased human cholangiocytes as an in vitro model to study primary sclerosing cholangitis. Laboratory Investigation, 2017, 97, 1385-1396.	3.7	39
146	Morphologic Demonstration of Receptor-Mediated Endocytosis of Epidermal Growth Factor by Isolated Bile Duct Epithelial Cells. Gastroenterology, 1990, 98, 1284-1291.	1.3	38
147	Development and characterization of a cholangiocyte cell line from the PCK rat, an animal model of Autosomal Recessive Polycystic Kidney Disease. Laboratory Investigation, 2006, 86, 940-950.	3.7	38
148	Effect of Chloroquine on the Form and Function of Hepatocyte Lysosomes Morphologic Modifications and Physiologic Alterations Related to the Biliary Excretion of Lipids and Proteins. Gastroenterology, 1983, 85, 1146-1153.	1.3	37
149	Cholangiocytes and the environment in primary sclerosing cholangitis: where is the link?. Gut, 2017, 66, 1873-1877.	12.1	37
150	Channel-mediated water movement across enclosed or perfused mouse intrahepatic bile duct units. American Journal of Physiology - Cell Physiology, 2002, 283, C338-C346.	4.6	36
151	Triton WR-1339, A Lysosomotropic Compound, Is Excreted into Bile and Alters the Biliary Excretion of Lysosomal Enzymes and Lipids. Hepatology, 1982, 2, 209S-215S.	7.3	36
152	HIVâ€1 Tat Protein Suppresses Cholangiocyte Tollâ€Like Receptor 4 Expression and Defense against<i>Cryptosporidium parvum</i>. Journal of Infectious Diseases, 2009, 199, 1195-1204.	4.0	36
153	Polycystic liver disease: New insights into disease pathogenesis. Hepatology, 2006, 43, 906-908.	7.3	35
154	Therapeutic Targets in Polycystic Liver Disease. Current Drug Targets, 2017, 18, 950-957.	2.1	35
155	Liver Stiffness Measured by Either Magnetic Resonance or Transient Elastography Is Associated With Liver Fibrosis and Is an Independent Predictor of Outcomes Among Patients With Primary Biliary Cholangitis. Journal of Clinical Gastroenterology, 2021, 55, 449-457.	2.2	34
156	Solute and Water Transport Pathways in Cholangiocytes. Seminars in Liver Disease, 1996, 16, 221-229.	3.6	32
157	Characterization of Apical and Basolateral Plasma Membrane Domains Derived from Cultured Rat Cholangiocytes. Analytical Biochemistry, 1997, 254, 192-199.	2.4	32
158	Cytoskeletal and motor proteins facilitate trafficking of AQP1â€containing vesicles in cholangiocytes. Biology of the Cell, 2006, 98, 43-52.	2.0	32
159	TLR4 Promotes Cryptosporidium parvum Clearance in a Mouse Model of Biliary Cryptosporidiosis. Journal of Parasitology, 2011, 97, 813-821.	0.7	32
160	Micro-computed tomography and nuclear magnetic resonance imaging for noninvasive, live-mouse cholangiography. Laboratory Investigation, 2013, 93, 733-743.	3.7	32
161	Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease. Mayo Clinic Proceedings, 2015, 90, 1030-1037.	3.0	32
162	Water movement across rat bile duct units is transcellular and channel-mediated. Hepatology, 2001, 34, 456-463.	7.3	31

#	Article	IF	Citations
163	Hepato-Renal Pathology in Pkd2/âˆ’ Mice, an Animal Model of Autosomal Dominant Polycystic Kidney Disease. American Journal of Pathology, 2010, 176, 1282-1291.	3.8	31
164	Dynamic measurements of the acute and chronic effects of lysosomotropic agents on hepatocyte lysosomal pH using flow cytometry. Hepatology, 1995, 22, 1519-1526.	7.3	30
165	Functional polarity of Na⁺/H⁺and Cl^{âˆ’}/ HCO 3 âˆ’ exchangers in a rat cholangiocyte cell line. American Journal of Physiology - Renal Physiology, 1998, 275, G1236-G1245.	3.4	30
166	Changes in Liver Stiffness, Measured by Magnetic Resonance Elastography, Associated With Hepatic Decompensation in Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2020, 18, 1576-1583.e1.	4.4	30
167	Physicochemical determinants in hepatic extraction of small peptides. Hepatology, 1990, 12, 76-82.	7.3	29
168	Pathobiology of biliary epithelia. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1220-1231.	3.8	29
169	Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target. Hepatology, 2018, 67, 1088-1108.	7.3	29
170	Primary Cilia in Tumor Biology: The Primary Cilium as a Therapeutic Target in Cholangiocarcinoma. Current Drug Targets, 2017, 18, 958-963.	2.1	29
171	AQP4 transfected into mouse cholangiocytes promotes water transport in biliary epithelia. Hepatology, 2004, 39, 109-116.	7.3	28
172	The enteric microbiome in hepatobiliary health and disease. Liver International, 2016, 36, 480-487.	3.9	28
173	Metabolomic Profiling of Portal Blood and Bile Reveals Metabolic Signatures of Primary Sclerosing Cholangitis. International Journal of Molecular Sciences, 2018, 19, 3188.	4.1	28
174	MicroRNAs in Cholangiopathies. Current Pathobiology Reports, 2014, 2, 133-142.	3.4	27
175	TGR5 in the Cholangiociliopathies. Digestive Diseases, 2015, 33, 420-425.	1.9	27
176	An Octogenarian With Acute Epigastric Pain: More Than Meets the Eye. Gastroenterology, 2016, 150, e5-e6.	1.3	26
177	ETS Proto-oncogene 1 Transcriptionally Up-regulates the Cholangiocyte Senescence-associated Protein Cyclin-dependent Kinase Inhibitor 2A. Journal of Biological Chemistry, 2017, 292, 4833-4846.	3.4	26
178	Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Seminars in Liver Disease, 2017, 37, 159-174.	3.6	26
179	Pharmacologic perturbation of rat liver lysosomes: Effects on release of lysosomal enzymes and of lipids into bile. Gastroenterology, 1988, 95, 1088-1098.	1.3	25
180	Early Cholangiocarcinoma Detection With Magnetic Resonance Imaging Versus Ultrasound in Primary Sclerosing Cholangitis. Hepatology, 2021, 73, 1868-1881.	7.3	25

#	Article	IF	Citations
181	The liver and intracellular digestion: How liver cells eat!. Hepatology, 1989, 10, 877-886.	7.3	24
182	Characterization and growth regulation of a rat intrahepatic bile duct epithelial cell line under hormonally defined, serum-free conditions. In Vitro Cellular and Developmental Biology - Animal, 1998, 34, 704-710.	1.5	24
183	Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1267-1278.	4.5	24
184	Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study. Scandinavian Journal of Gastroenterology, 2019, 54, 633-639.	1.5	23
185	MicroRNAs in cholangiociliopathies. Cell Cycle, 2009, 8, 1324-1328.	2.6	22
186	The transcription factor ETS1 promotes apoptosis resistance of senescent cholangiocytes by epigenetically up-regulating the apoptosis suppressor BCL2L1. Journal of Biological Chemistry, 2019, 294, 18698-18713.	3.4	22
187	Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets. Liver International, 2020, 40, 1670-1685.	3.9	22
188	An update on primary sclerosing cholangitis epidemiology, outcomes and quantification of alkaline phosphatase variability in a population-based cohort. Journal of Gastroenterology, 2020, 55, 523-532.	5.1	22
189	Senescent cholangiocytes release extracellular vesicles that alter target cell phenotype via the epidermal growth factor receptor. Liver International, 2020, 40, 2455-2468.	3.9	20
190	Cholangiocyte biology. Current Opinion in Gastroenterology, 2006, 22, 279-287.	2.3	19
191	Fibrolamellar hepatocellular carcinoma presenting with budd-chiari syndrome, right atrial thrombus, and pulmonary emboli. Hepatology, 2012, 55, 977-978.	7.3	19
192	Centrosomal Abnormalities Characterize Human and Rodent Cystic Cholangiocytes and Are Associated with Cdc25A Overexpression. American Journal of Pathology, 2014, 184, 110-121.	3.8	19
193	Regulated vesicle trafficking of membrane transporters in hepatic epithelia. Journal of Hepatology, 2005, 42, 592-603.	3.7	18
194	MicroRNAs in the Cholangiopathies: Pathogenesis, Diagnosis, and Treatment. Journal of Clinical Medicine, 2015, 4, 1688-1712.	2.4	18
195	MicroRNAs and Benign Biliary Tract Diseases. Seminars in Liver Disease, 2015, 35, 026-035.	3.6	17
196	Genetic or pharmacological reduction of cholangiocyte senescence improves inflammation and fibrosis in the Mdr2Âmouse. JHEP Reports, 2021, 3, 100250.	4.9	17
197	Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease. American Journal of Pathology, 2018, 188, 981-994.	3.8	16
198	Cellular senescence in the cholangiopathies: a driver of immunopathology and a novel therapeutic target. Seminars in Immunopathology, 2022, 44, 527-544.	6.1	16

#	Article	IF	Citations
199	Polycystic Liver Disease: The Benefits of Targeting cAMP. Clinical Gastroenterology and Hepatology, 2016, 14, 1031-1034.	4.4	15
200	Recent advances in the isolation of liver cells. Hepatology, 1994, 20, 494-514.	7.3	15
201	Polycystic Liver Disease: Advances in Understanding and Treatment. Annual Review of Pathology: Mechanisms of Disease, 2022, 17, 251-269.	22.4	15
202	Long non-coding RNA ACTA2-AS1 promotes ductular reaction by interacting with the p300/ELK1 complex. Journal of Hepatology, 2022, 76, 921-933.	3.7	15
203	Genetics, pathobiology and therapeutic opportunities of polycystic liver disease. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 585-604.	17.8	15
204	Role of the Intestinal Microbiome in Cholestatic Liver Disease. Digestive Diseases, 2017, 35, 166-168.	1.9	14
205	Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models. Journal of Hepatology, 2021, 74, 394-406.	3.7	14
206	Hepatic extraction of renin: Quantitation and characterization in the isolated perfused rat liver. Hepatology, 1987, 7, 1254-1261.	7.3	13
207	Polycystic liver disease: The interplay of genes causative for hepatic and renal cystogenesis. Hepatology, 2018, 67, 2462-2464.	7.3	13
208	Induced Pluripotent Stem Cells From Subjects With Primary Sclerosing Cholangitis Develop a Senescence Phenotype Following Biliary Differentiation. Hepatology Communications, 2022, 6, 345-360.	4.3	12
209	Lack of metabolic effects of cholecystokinin on hepatocytes. Hepatology, 1990, 12, 301-305.	7.3	11
210	Charcoal hemoperfusion in the treatment of medically refractory pruritus in cholestatic liver disease. Hepatology International, 2017, 11, 384-389.	4.2	11
211	Polarized human cholangiocytes release distinct populations of apical and basolateral small extracellular vesicles. Molecular Biology of the Cell, 2020, 31, 2463-2474.	2.1	11
212	Immunotherapy-based targeting of MSLN ⁺ activated portal fibroblasts is a strategy for treatment of cholestatic liver fibrosis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	11
213	Experimental models to study cholangiocyte biology. World Journal of Gastroenterology, 2002, 8, 1.	3.3	11
214	Highâ€Resolution Exposomics and Metabolomics Reveals Specific Associations in Cholestatic Liver Diseases. Hepatology Communications, 2022, 6, 965-979.	4.3	11
215	Quantitative importance of biliary excretion to the turnover of hepatic lysosomal enzymes. Hepatology, 1995, 22, 262-266.	7.3	9
216	Isolation of Primary Cilia for Morphological Analysis. Methods in Cell Biology, 2009, 94, 103-115.	1.1	9

#	Article	IF	Citations
217	Cholangiocyte Myosin IIB Is Required for Localized Aggregation of Sodium Glucose Cotransporter 1 to Sites of<i>Cryptosporidium parvum</i>Cellular Invasion and Facilitates Parasite Internalization. Infection and Immunity, 2010, 78, 2927-2936.	2.2	9
218	Calcium signaling in cilia and ciliary-mediated intracellular calcium signaling: Are they independent or coordinated molecular events?. Hepatology, 2014, 60, 1783-1785.	7.3	9
219	Cellular senescence in the cholangiopathies. Current Opinion in Gastroenterology, 2022, 38, 121-127.	2.3	9
220	Current therapies and clinical controversies in the management of primary sclerosing cholangitis. Current Gastroenterology Reports, 2000, 2, 99-103.	2.5	7
221	B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease inÂaÂratÂmodel of polycystic kidney disease. Kidney International, 2017, 92, 657-668.	5.2	7
222	The metabolic bone disease of primary sclerosing cholangitis. Hepatology, 1991, 14, 257-261.	7.3	7
223	Autophagy promotes hepatic cystogenesis in polycystic liver disease by depletion of cholangiocyte ciliogenic proteins. Hepatology, 2022, 75, 1110-1122.	7.3	7
224	Bacterial Cholangitis in Autosomal Dominant Polycystic Kidney and Liver Disease. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2019, 3, 149-159.	2.4	4
225	Autophagy-mediated reduction of miR-345 contributes to hepatic cystogenesis in polycystic liver disease. JHEP Reports, 2021, 3, 100345.	4.9	4
226	Physiology of Cholangiocytes. , 2006, , 1505-1533.		4
227	Cholangiocyte biology. Current Opinion in Gastroenterology, 2005, 21, 337-343.	2.3	3
228	Physiology of Cholangiocytes. , 2012, , 1531-1557.		3
229	Cholangiocyte biology. Current Opinion in Gastroenterology, 2002, 18, 360-365.	2.3	2
230	G astroenterology 's Editors-in-Chief: Historical and Personal Perspectives of Their Editorships. Gastroenterology, 2013, 145, 16-31.	1.3	2
231	Physiology of Cholngiocytes. , 2018, , 1003-1023.		2
232	Cholangiocytes in health and disease: From basic science to novel treatments. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1217-1219.	3.8	2
233	Pancreatobiliary Ductal Dilatation: Unique Pathobiological Processes and Endoscopic Revelations. Gastroenterology, 2019, 156, 876-878.	1.3	2
234	DNA methylation profile of liver tissue in end-stage cholestatic liver disease. Epigenomics, 2022, 14, 481-497.	2.1	2

#	Article	IF	Citations
235	Patients, cells, and organelles: The intersection of science and serendipity. Hepatology, 2011, 53, 1417-1426.	7.3	1
236	Microbiomeâ€immune interactions and liver disease. Clinical Liver Disease, 2015, 5, 83-85.	2.1	1
237	Doublecortin domain containing protein 2 (DCDC2) genetic variants in primary sclerosing cholangitis. Journal of Hepatology, 2017, 67, 651-652.	3.7	1
238	A 59-Year-Old Man With New Jaundice. Gastroenterology, 2018, 154, 2035-2036.	1.3	1
239	Cholangiocyte Biology. , 2017, , 83-97.		1
240	Comparative Performance of Quantitative and Qualitative Magnetic Resonance Imaging Metrics in Primary Sclerosing Cholangitis. , 2022, 1, 287-295.		1
241	Portal fibroblasts: A renewable source of liver myofibroblasts. Hepatology, 2022, 76, 1240-1242.	7.3	1
242	Cholangiocyte biology. Current Opinion in Gastroenterology, 2003, 19, 264-269.	2.3	0
243	Cholangiocyte Cilia and Basal Bodies. , 2010, , 45-70.		0